DOSES STUDIED
Ipamorelin dosage, as the published studies actually administered it.
A research-context record of doses, routes, and durations — what was given to which species, and what the human data do and do not cover.
Read this first
This page describes Ipamorelin dosage strictly as it appears in published research — the amounts, routes, and durations that scientists administered to people or animals in specific studies. It is a record, not a guide. There is no human dosing recommendation here, because the evidence does not support one: the human data come from a single pharmacokinetic study and one failed trial, both intravenous, in clinical settings. The doses people use in the community are subcutaneous and have no peer-reviewed human basis. Everything below is written as "this study gave this dose to this species by this route." If you take one thing from this page, let it be that the studied human doses were intravenous and supervised, and that the popular self-injected protocols are not backed by any published human dosing science.
The human doses on record
Only two human datasets exist, and both used the intravenous route. The pharmacokinetic study gave healthy men single intravenous infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes, mapping dose-proportional kinetics and the roughly 2-hour half-life [2]. The Phase 2 ileus trial gave 0.03 mg/kg intravenously twice daily for up to seven days after bowel surgery — and that regimen missed its efficacy endpoint [3]. That is the entirety of the human dosing record: acute IV pharmacology, and one short perioperative IV course that did not work. No oral, subcutaneous, or intranasal human dosing has been formally characterized in the peer-reviewed literature.
The animal doses, by route
The animal record is broader and spans several routes. In a rat bone-growth study, subcutaneous ipamorelin was given at 18, 90, and 450 micrograms/day, divided three times daily for 15 days, producing dose-dependent longitudinal bone growth [4]. The 2024 ferret cachexia study used intraperitoneal ipamorelin at 1-3 mg/kg [5]. Across the research-supply literature, subcutaneous injection is the dominant route used in rodent body-composition work and is also the route community users adopt — but the rodent doses do not translate to a human dose, and the community route has no published human pharmacokinetics.
How much cjc-1295 ipamorelin should i take
There is no evidence-based answer to "how much cjc-1295 ipamorelin should i take," and the honest appraisal is to say so directly. No controlled human trial of the ipamorelin cjc-1295 combination has been conducted for any outcome — the rationale for pairing them is mechanistic, demonstrated in rodents where GHRH and a GHRP produced synergistic growth-hormone release greater than the sum of each alone [12]. Community "stack" protocols that circulate online are anecdotal: they have no peer-reviewed human dosing basis and are not a recommendation. This site does not provide a combination dose because no published human dosing science exists to ground one.
How to reconstitute cjc-1295 ipamorelin 5mg
On "how to reconstitute cjc-1295 ipamorelin 5mg," the only thing the research-supply literature supports is general peptide-handling description, not a clinical preparation instruction. Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — and as a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solutions are typically kept refrigerated. These are general handling observations from the research-supply literature, framed for laboratory use. They are not a protocol for human administration, and this site offers none. The studied human routes were intravenous and supervised [2][3].
Half-life and clearance, in context
The pharmacokinetics are the firmest dosing-adjacent data ipamorelin has. The human terminal half-life is approximately 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is not a sustained elevation but a single discrete pulse peaking about 40 minutes after dosing [2]. In rats, plasma clearance runs roughly 5-fold lower than GHRP-6. A short half-life and a single-pulse response are the pharmacological reasons community protocols favor frequent, often pre-sleep, dosing — but that is an inference from the PK, not a studied human schedule. The dedicated how long does ipamorelin stay in your system page reads the clearance data in full.